Pradaxa Lawsuit Information: The
Blood Thinner Pradaxa Can Cause Excessive Bleeding and Has No Known
Antidote or Reversal Agent Which Can Cause Death in Patients Taking the Blood Thinner by Texas Pradaxa Lawyer
Jason Coomer
Pradaxa
has been marketed as a new and improved blood thinner to replace
existing successful blood thinners. Pradaxa has the usual side effects
and health risks of other blood thinners which includes excessive
bleeding. However, unlike older blood thinners, Pradaxa has two
important differences:
- Pradaxa has no known reversal agent or antidote, and
- There is no standard method with which to measure the anticoagulant effects of Pradaxa.
Pradaxa
Has Been Marketed As A New And Improved Blood Thinner That Has Been
Added To Numerous Hospital Formularies As An Established Blood Thinner
Allowing Pradaxa To Rapidly Gain Market Share and Expanding Its Use
Pradaxa
(dabigatran etexilate mesylate) is a direct thrombin inhibitor
anticoagulant, which became FDA-approved on October 29, 2010. Pradaxa
reduces the risk of stroke and systemic embolism in patients with
non-valvular atrial fibrillation. Pradaxa is being marketed to be
prescribed and used to replace existing successful blood thinners
such as Warfarin (Coumadin). Within the first seven months after
Pradaxa's approval, more than 250,000 patients were prescribed
Pradaxa. In July 2011, Boehringer Ingelheim Pharmaceuticals, Inc.
(BIPI) announced that Pradaxa (dabigatran etexilate mesylate)
capsules had been added to hospital formularies at 49 of the top 50
cardiology and heart surgery hospitals in the United States. In
other words Pradaxa was added as the blood thinner of choice in
formularies that insure about 90 percent of covered lives in the U.S.
Boehringer
Ingelheim has successfully marketed Pradaxa as an improvement over
other blood thinners. However, Pradaxa has already led to hundreds
of reports of deaths and many other serious life-threatening injuries.
Large
Drug Companies That Influence Standards of Care Including Hospital
Formularies Through Marketing Fraud and Fraudulent Research Can Be Held
Liable For Medicaid Fraud and Medicare Fraud Through Whistleblower
Reward Lawsuits
Many
health care professions have become aware of the strong
influence that drug companies now have in determining community
standards of care for medication use in patients. These drug
companies often push drug samples into many hospitals and use
powerful forms of manipulation including biased research,
influencing key medical doctors, and kickbacks to get their drugs
placed on hospital formularies.
Whistleblowers that are the first to file on these fraudulent practices can expose fraud and obtain large whistleblower rewards for exposing fraud. These medical professionals and pharmaceutical professionals can also have a drug formulary fraud whistleblower reward lawyer confidentially review a potential case prior to stepping forward. For more information on Drug Formulary Fraud Whistleblower Reward Lawsuits, please feel free to go to the following web page: Drug Formulary Fraud Whistleblower Reward Lawsuit.
Whistleblowers that are the first to file on these fraudulent practices can expose fraud and obtain large whistleblower rewards for exposing fraud. These medical professionals and pharmaceutical professionals can also have a drug formulary fraud whistleblower reward lawyer confidentially review a potential case prior to stepping forward. For more information on Drug Formulary Fraud Whistleblower Reward Lawsuits, please feel free to go to the following web page: Drug Formulary Fraud Whistleblower Reward Lawsuit.
Pradaxa Lawsuit Information: The Blood Thinner Pradaxa Can Cause Excessive Bleeding and Has No Known
Antidote or Reversal Agent Which Can Cause Death in Patients Taking the Blood Thinner
For more information on this topic, please feel free to go to the following web page: Pradaxa Lawsuit Information or please feel free to send an e-mail message to Pradaxa Lawyer, Jason Coomer.